The world of biomedical science has long relied on a unique and irreplaceable natural resource: the blood of horseshoe crabs. This ancient species, often referred to as “living fossils,” has played a critical role in ensuring the safety of injectable drugs and medical devices for decades. However, this reliance on horseshoe crab blood, particularly in the form of Limulus Amebocyte Lysate (LAL) reagent, has put these creatures under immense pressure. The increasing demand for LAL, coupled with the dwindling population of horseshoe crabs, has led to a pressing need for alternative methods of endotoxin detection.

The United States Pharmacopeia (USP) has taken a significant step towards addressing this issue. On July 26, 2024, the USP Expert Committee approved the inclusion of USP<86> Bacterial Endotoxins Test Using Recombinant Reagents in the “United States Pharmacopeia-National Formulary.” This new chapter, set to be published in November 2024 and taking effect in May 2025, marks a pivotal moment in the shift towards more sustainable and ethical testing methods.

The Importance of Endotoxin Detection

Endotoxins, also known as lipopolysaccharides (LPS), are potent toxins found in the outer membrane of Gram-negative bacteria. They can cause severe inflammatory responses, leading to fever, septic shock, and even death in humans. As a result, the detection of endotoxins is a crucial quality control measure in the production of biologics, injectable drugs, vaccines, and medical devices.

For years, the Limulus Amebocyte Lysate (LAL) test has been the gold standard for endotoxin detection. Derived from the blue blood of horseshoe crabs, LAL reacts with endotoxins, causing a gelation reaction that can be measured to determine endotoxin levels. However, the reliance on this test has raised significant ethical and environmental concerns.

The Impact on Horseshoe Crabs

Horseshoe crabs, particularly the Chinese horseshoe crab (Tachypleus tridentatus), have been classified as endangered by the International Union for Conservation of Nature (IUCN) since March 2019. The extraction of their blood for LAL production has contributed to the decline of their populations, threatening the survival of these ancient creatures.

The biomedical industry’s growing demand for LAL reagents has exacerbated the conflict between public health needs and the conservation of horseshoe crabs. This situation has prompted scientists and researchers to develop alternative methods for endotoxin testing that do not rely on the

Endotoxin Detection Methods

To address the ethical and environmental challenges posed by the LAL test, several alternative methods for endotoxin detection have been developed. These include the Rabbit Pyrogen Test (RPT), Monocyte Activation Test (MAT), and Recombinant Factor C (rFC) test. Each of these methods offers a different approach to detecting endotoxins, with varying degrees of specificity, sensitivity, and practicality.

1. Rabbit Pyrogen Test (RPT)

The Rabbit Pyrogen Test (RPT) is one of the oldest methods for detecting pyrogens, including endotoxins. In this test, a sample is injected into rabbits, and their body temperature is monitored for any signs of fever. While this method is effective in detecting a wide range of pyrogens, it is not specific to endotoxins and raises ethical concerns due to the use of live animals.

2. Monocyte Activation Test (MAT)

The Monocyte Activation Test (MAT) is a more modern approach to pyrogen detection. It measures the release of cytokines, such as interleukin-1β, from human monocytes in response to pyrogens. This test is not only more humane but also offers greater sensitivity and specificity compared to the RPT. However, its use is still limited compared to the more established LAL test.

3. Limulus Amebocyte Lysate (LAL) Test

The LAL test, derived from horseshoe crab blood, remains the most widely used method for endotoxin detection. It is highly sensitive and specific to endotoxins, making it the standard method for quality control in the pharmaceutical industry. However, the ethical and environmental concerns associated with the use of horseshoe crab blood have driven the search for alternatives.

4. Recombinant Factor C (rFC) Test

The Recombinant Factor C (rFC) test is a groundbreaking alternative to the LAL test. It uses a genetically engineered version of Factor C, the protein in horseshoe crab blood that reacts with endotoxins. This recombinant protein can be produced without harming horseshoe crabs, making it a more sustainable and ethical option. The rFC test offers comparable sensitivity and specificity to the LAL test, making it a promising alternative for the future of endotoxin detection.

The Emergence of Recombinant Factor C (rFC) Testing

One of the most significant advancements in endotoxin detection has been the development of the Recombinant Factor C (rFC) test. This innovative method represents a major step forward in reducing the reliance on horseshoe crab blood while maintaining the high standards of safety required in the biomedical industry.

How rFC Testing Works

The rFC test works by utilizing a recombinant version of the Factor C protein found in horseshoe crab blood. This protein is responsible for the activation of the clotting cascade in response to endotoxins. In the rFC test, the recombinant Factor C is activated by binding to endotoxins, which then cleaves a fluorescent substrate to release free fluorescent groups. The amount of fluorescence produced is directly proportional to the concentration of endotoxins in the sample, allowing for quantitative detection.

Advantages of rFC Testing

The rFC test offers several advantages over traditional LAL testing:

– Ethical Considerations: The rFC test eliminates the need for horseshoe crab blood, addressing the ethical concerns associated with LAL testing.

– Environmental Impact: By reducing the demand for horseshoe crab blood, the rFC test helps to protect endangered horseshoe crab populations and preserve biodiversity.

– Consistency and Reliability: The rFC test is not subject to the same batch-to-batch variability seen with LAL reagents, ensuring more consistent and reliable results.

– Specificity and Sensitivity: The rFC test offers comparable specificity and sensitivity to the LAL test, making it a viable alternative for endotoxin detection in a wide range of application

The Role of Hzymes Biotech in Endotoxin Detection

Hzymes Biotech, a leading innovator in the field of biotechnology, has been at the forefront of developing and commercializing the rFC test. Their Recombinant C Factor Endotoxin Detection Kit represents the future of endotoxin testing, offering a sustainable, ethical, and highly accurate alternative to traditional methods.

Product Performance

Hzymes Biotech’s Recombinant C Factor Endotoxin Detection Kit offers several key features that make it an ideal choice for endotoxin detection:

– Easy Operation: The kit features a one-step detection process with endpoint fluorescence determination, allowing for rapid and straightforward testing. The detection time is only 90 minutes, making it a time-efficient option for laboratories.

– Excellent Performance: The kit boasts high sensitivity (0.005EU/mL~5EU/mL), ensuring accurate detection of even low levels of endotoxins. It also offers good batch-to-batch and intra-batch consistency, with sample recovery rates meeting industry standards.

– Exclusive Specificity: Unlike traditional LAL tests, the Recombinant C Factor Endotoxin Detection Kit is not affected by G factor bypass interference, making it suitable for endotoxin detection in samples with β-glucan interference. This feature helps to avoid false positives and ensures accurate results.

– Long Stability: The lyophilized standard in the kit can be stored at 4°C for up to 60 days after reconstitution, providing long-term stability and convenience. The kit itself can be stably stored for up to one year, ensuring its readiness for use when needed.

– Wide Applicability: The kit is versatile and suitable for various types of sample detection. It is compatible with multiple microplate readers, allowing for seamless integration into existing laboratory workflows.

Product Ordering

Hzymes Biotech offers the Recombinant C Factor Endotoxin Detection Kit in two formats:

– HBP008001-1: 48 tests per kit

– HBP008001-2: 96 tests per kit

These options provide flexibility for laboratories of different sizes and testing needs, ensuring that they can find a solution that fits their specific requirements.

The Future of Endotoxin Detection: A Sustainable Path Forward

The approval of USP<86> Bacterial Endotoxins Test Using Recombinant Reagents marks a turning point in the field of endotoxin detection. As the new standard takes effect in May 2025, the biomedical industry will increasingly shift towards using recombinant reagents, reducing the reliance on horseshoe crab blood and promoting more sustainable practices.

This shift is not just about protecting endangered species; it is also about embracing innovation and ensuring the highest standards of safety and accuracy in medical testing. The development of the rFC test and its adoption by companies like Hzymes Biotech represent a crucial step towards a more ethical and environmentally responsible future.

Conclusion

The urgent need to protect endangered species like the horseshoe crab has catalyzed a revolution in endotoxin detection methods. The approval of USP<86> and the development of recombinant reagents like the rFC test are paving the way for a future where the safety of medical products does not come at the expense of the environment or ethical standards.

Hzymes Biotech’s Recombinant C Factor Endotoxin

In the future, Hzymes biotech will always remember its original intention and persist in meticulous cultivation in the IVD field. It will adhere to independent research and development, accelerate the construction of a world-class specialty enzyme production platform, and achieve import substitution of core enzyme raw materials in the field of biomedicine in China. It will collaborate with leading biopharmaceutical companies to expand their global presence and contribute to the advancement of the industry.